Study: People on a weight-loss shot who lifted weights three times a week got stronger, while those who didn’t got weaker, even though both lost about 50 pounds
In a 40-week trial of 120 adults ages 50 to 70 taking tirzepatide, the drug sold as Mounjaro and Zepbound, weight training cut muscle and lean-tissue loss by about a quarter.
On Hold: health study (Tier 2 gate for health claims); editor to confirm Life vs. Medicine section; stock photo of equipment, not people
If you’re taking one of the new weight-loss drugs, lifting weights may help you keep your strength, a new study suggests. In a 40-week trial, people on the drug tirzepatide who did weight training three times a week lost about 25% less lean tissue, which includes muscle, and got about 10% stronger, while people on the drug alone got about 10% weaker, the University of Western Australia reported.
Both groups lost almost the same amount of weight: about 22.3 to 22.6 kilograms, or roughly 49 to 50 pounds, most of it fat, according to the study in Nature Medicine, a peer-reviewed medical journal, published Nov. 9.
Tirzepatide is the drug in Eli Lilly’s Mounjaro and Zepbound. Like semaglutide (Ozempic and Wegovy), it mimics gut hormones that curb appetite. Doctors have worried that fast weight loss on these drugs also strips away muscle, which matters more as people age because weaker muscles raise the risk of falls.
What the study found
- Muscle: People on the drug alone lost about 4.7 kilograms (about 10 pounds) of lean tissue. Those who also lifted lost about 3.6 kilograms (about 8 pounds).
- Strength: On the drug alone, bench press, lat pulldown and leg strength all fell by about 4 to 4.4 kilograms. With training, they rose by about 4.7 to 8.6 kilograms.
- Sticking with it: Participants made it to 91% of their workouts, the researchers wrote.
How the study worked
Researchers in Perth, Australia, gave 120 adults ages 50 to 70, half men and half women past menopause, weekly tirzepatide shots for 40 weeks. All had obesity, or were overweight with a weight-related health problem, and none had Type 2 diabetes. Half were randomly assigned to three supervised weight-training sessions a week at a center; the other half kept up their usual activities.
Eli Lilly, which makes tirzepatide, supplied the drug free but had no other role in the trial, the authors wrote. Other support came from Australian government research awards. Several authors have received speaking fees from drug companies including Lilly and Novo Nordisk, the paper discloses.
What it doesn’t show
The trial was small and lasted 40 weeks, so it can’t say whether the strength gains last or lower the risk of falls or other health problems over years. Workouts were supervised at a center three times a week, which may be hard to match on your own. And it tested only tirzepatide, not other weight-loss drugs. The scans measured lean tissue, which includes muscle but also organs and water, not muscle alone.
What this means
For people on a weight-loss shot, adding regular strength training may protect strength without slowing weight loss. If you take one of these drugs, or are thinking about it, ask your doctor what kind of exercise is right for you before starting a new routine.
Source: Green D.J. et al., Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial, Nature Medicine, Nov. 9, 2026, and the University of Western Australia release, checked Nov. 20, 2026.
- Nature Medicine: Green et al., Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity (RCT), Nov. 9, 2026 (open access)
- University of Western Australia: Resistance training key to maintaining muscle function during GLP-1 weight loss (Nov. 10, 2026)
- Nature research highlight: Lifting weights reduces muscle loss from obesity drugs (Nov. 20, 2026)